LOU064D
Total Payments
$11,890
Transactions
8
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $5,465 | 4 | 0 |
| 2019 | $6,425 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,890 | 8 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, SUBJECT- AND INVESTIGATOR- BLINDED, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LOU064 IN PATIENTS WITH INADEQUATELY CONTROLLED ASTHMA | Novartis Pharmaceuticals Corporation | $11,890 | 0 |
Top Doctors Receiving Payments for LOU064D
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Raleigh, NC | $11,890 | 8 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $11,890
- Total Doctors 0
- Transactions 8
About LOU064D
LOU064D is a drug associated with $11,890 in payments to 0 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2019 to 2020. In 2020, $5,465 was paid across 4 transactions to 0 doctors.
The most common payment nature for LOU064D is "Unspecified" ($11,890, 100.0% of total).
LOU064D is associated with 1 research study, including "A RANDOMIZED, SUBJECT- AND INVESTIGATOR- BLINDED, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LOU064 IN PATIENTS WITH INADEQUATELY CONTROLLED ASTHMA" ($11,890).